

Placement of a Sodium Hyaluronate Solution onto the Liver Surface as a Supportive Procedure for Radiofrequency Ablation of Hepatocellular Carcinomas Located on the Liver Surface: A Preliminary Report

Hidenori Toyoda, MD, PhD, Takashi Kumada, MD, PhD, Toshifumi Tada, MD, Yuji Kaneoka, MD, PhD, and Atsuyuki Maeda, MD, PhD

ABSTRACT

Purpose: To evaluate safety and efficacy of the placement of sodium hyaluronate solution onto the liver surface as a supportive procedure for radiofrequency (RF) ablation of hepatocellular carcinomas (HCCs) located on the liver surface as a possible alternative to RF ablation via laparoscopic approach or with the creation of artificial ascites.

Materials and Methods: Changes in temperature of a sodium hyaluronate layer placed onto an egg white were measured during coagulation of the egg white by an RF ablation needle. A phase I study was performed to evaluate the safety of intraperitoneal injection of a maximum of 20 mL of sodium hyaluronate solution into humans by observing for the occurrence of intraperitoneal inflammation and adhesion. After these studies, RF ablation with ultrasound-guided injection of sodium hyaluronate onto the liver surface was performed, targeting 28 HCC nodules located on the liver surface. Treatment outcomes and complications of this procedure were investigated.

Results: In the *in vitro* experiment, the maximum temperature of sodium hyaluronate solution was 41°C during RF ablation. No intraperitoneal inflammation or adhesions were observed after intraperitoneal injection of sodium hyaluronate in the phase I study. HCC was completely ablated with sufficient margins after one session of RF ablation, without any burn injuries to the abdominal wall or adjacent organs. Local recurrence was observed in one of 28 patients (3.6%) during 30.1 months of follow-up.

Conclusions: RF ablation can be safely and effectively performed on HCCs located close to the liver surface with placement of sodium hyaluronate onto the liver surface, thereby preventing burn injuries to abdominal wall or adjacent organs.

ABBREVIATIONS

CRP = C-reactive protein, HCC = hepatocellular carcinoma, RF = radiofrequency, WBC = white blood cell

From the Departments of Gastroenterology (H.T., T.K., T.T.) and Surgery (Y.K., A.M.), Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. Received May 26, 2012; final revision received August 16, 2012; accepted August 24, 2012. Address correspondence to H.T.; E-mail: tkumada@he.mirai.ne.jp

None of the authors have identified a conflict of interest.

This article includes Figures E1 and E2, which are available online at www.jvir.org.

© SIR, 2012

J Vasc Interv Radiol 2012; 23:1639–1645

<http://dx.doi.org/10.1016/j.jvir.2012.08.024>

Radiofrequency (RF) ablation is currently one of the standard treatment modalities for hepatocellular carcinoma (HCC) and, along with hepatic resection, is potentially curative (1–3). However, problems have been reported with the use of RF ablation for HCCs that are located close to the liver surface; these adverse effects include damage to the abdominal wall or to adjacent organs such as the gallbladder and gastrointestinal tract (4–6). RF ablation via laparoscopic approach (7–9) and RF ablation with the creation of artificial ascites (10,11) have been employed in the ablation of tumors located near the liver surface. These supportive procedures for RF ablation are used to prevent damage to the abdominal wall or adjacent organs by separating the ablation area from adjacent structures.

However, RF ablation via laparoscopic approach usually requires general anesthesia. In addition, RF ablation via laparoscopic approach or creation of artificial ascites may cause vascular and respiratory complications as a result of increased intraperitoneal pressures (12,13).

Sodium hyaluronate solutions have been used in various clinical fields. In orthopedics, a sodium hyaluronate solution is used in intraarticular injections for osteoarthritis (14,15). In ophthalmology, the solution is used in intralenticular injections during cataract surgery (16). In gastroenterology, the solution is used as a submucosal fluid cushion during the endoscopic resection of mucosal neoplasms in the stomach or colon (17–20). Because sodium hyaluronate has a high viscosity (limiting viscosity of 11.8–19.5 dL/g) and remains at the injection site for a considerable length of time, the solution can effectively continue to separate the two objects between which it is injected. The compound creates a durable separation between the submucosal and muscle layers during endoscopic mucosal resections. Therefore, it may be possible to create a continuous separation between the liver surface and the abdominal wall or adjacent organs by injecting sodium hyaluronate onto the liver surface. Moreover, it may be possible to perform RF ablation of HCCs that are located close to the liver surface without using the laparoscopic approach or creating artificial ascites while still preventing damage to the abdominal wall or adjacent organs.

MATERIALS AND METHODS

In Vitro Experiment: Sodium Hyaluronate Temperature Determination during RF Ablation

The change in temperature of sodium hyaluronate solution during the RF ablation procedure was initially investigated in an in vitro experiment. In a beaker, 20 mL of a 0.4% sodium hyaluronate solution (MucoUp; Johnson and Johnson, Tokyo, Japan) was placed on the surface of raw egg whites, creating an approximately 1.8-cm layer of the sodium hyaluronate solution. An RF electrode that was equipped with a 3-cm exposed metallic tip (Cool-tip; Covidien, Mansfield, Massachusetts) was inserted into this beaker. The electrode that was used for thermal ablation was positioned with its tip in the egg white layer and part of its exposed portion in the sodium hyaluronate layer. Temperature changes in the sodium hyaluronate layer were continuously monitored by using another RF electrode, the tip of which was placed in the middle of the sodium hyaluronate solution when the egg white was heated (Fig 1). This procedure was continued until the heated egg white coagulated. The experiment was repeated three times.

Phase I Study: Safety of Intraperitoneal Sodium Hyaluronate Injection

After obtaining approval from the institutional ethics committee and written informed consent from each individual,




Figure 1. In vitro determination of temperature increases in the sodium hyaluronate solution associated with thermal ablation by an RF ablation needle. A 0.4% sodium hyaluronate solution layer was placed onto a layer of egg whites in a beaker (A). Subsequently, an RF ablation needle electrode for thermal ablation (B) was inserted with the tip in the egg white layer and the proximal end of the exposed tip (C) in the sodium hyaluronate layer. Another electrode to monitor the temperature of the sodium hyaluronate solution (D) was inserted into the sodium hyaluronate solution layer. The images display the results after 3 minutes (a) and 8 minutes (b) of thermal ablation. The volume of the coagulated egg whites increased with thermal ablation (E). (Available in color online at www.jvir.org.)

a phase I study was performed to evaluate the safety of intraperitoneal injection of the sodium hyaluronate solution into humans. A 0.4% sodium hyaluronate solution (MucoUp; Johnson and Johnson) was injected percutaneously onto the liver surface under ultrasound (US) guidance with a 21-gauge needle (PEIT needle; Hakko, Nagano, Japan) that is usually used for ethanol injection therapy. The sodium hyaluronate solution was injected into six patients in a dose-escalating manner, ie, 5 mL, 10 mL, and 20 mL in two patients each. Laboratory tests were performed on day 3 after the injection to determine whether white blood cell (WBC) counts and C-reactive protein (CRP) values would increase as a result of inflammation caused by intraperitoneal injection of the sodium hyaluronate solution. The US examination was performed 5–7 days after the injection to determine whether ileus would occur as a result of peritoneal adhesions caused by the intraperitoneal injection.

RF Ablation of HCC with Sodium Hyaluronate Solution on the Liver Surface

After obtaining approval from the institutional ethics committee (based on the in vitro experiment and the phase I study) and written informed consent from each subject, RF ablation of the HCCs was performed with the placement of a sodium hyaluronate solution onto the liver surface. Between July 2009 and December 2011, 294 patients underwent RF ablation as a treatment of primary or recurrent HCCs. Patients with no more than three (≤ 3) HCC tumors at

largest 3 cm in maximum diameter were considered to be candidates for RF ablation. Patients with Child–Pugh Class C cirrhosis and patients with platelet counts of less than 50×10^3 were not considered for RF ablation. HCC tumors were located on the liver surface or close to the liver surface in 28 patients who were treated with RF ablation with placement of sodium hyaluronate solution onto the liver surface. For all patients, the diagnosis of HCC was made by observing the appropriate imaging characteristics based on criteria in the guidelines issued by the American Association for the Study of Liver Diseases (21).

All patients were placed in the supine position for treatment. A sodium hyaluronate solution was placed onto the liver surface where the HCC was located by injecting the solution percutaneously through a 21-gauge needle (PEIT needle; Hakko) under real-time US guidance. The sodium hyaluronate solution was injected until the thickness of the sodium hyaluronate layer reached approximately 1–2 cm. The needle was withdrawn after the sodium hyaluronate solution was injected and before RF ablation was performed.

After placement of the sodium hyaluronate solution onto the liver surface, RF ablation was performed with use of a 20-cm-long, 17-gauge RF electrode equipped with a 2-cm or 3-cm exposed metallic tip and connected to a 500-kHz RF generator (Cool-tip; Covidien). The electrode was inserted percutaneously under real-time US guidance and positioned accurately within the tumor. The length of the exposed metallic tip (2 or 3 cm) was determined based on the HCC tumor size. RF ablation durations were 8 minutes with a 2-cm exposed tip and 12 minutes with a 3-cm exposed tip, according to the manufacturer's recommendations. If there were fewer than four occurrences of power roll-off during these ablation periods, the duration of ablation was increased until four power roll-offs occurred. The distance between the tumor and adjacent structures was monitored by real-time US throughout the RF ablation procedure.

The occurrence of abdominal pain or fever was prospectively surveyed by clinical examination during the 3 days after RF ablation, and WBC counts and CRP levels were measured on the first day after RF ablation to determine whether there were signs or symptoms of burn injuries to the abdominal wall or other organs adjacent to the tumor treated by RF ablation. Evaluation of treatment response was performed 1–3 days after the RF ablation procedure by imaging examinations, including contrast-enhanced US and either contrast-enhanced computed tomography (CT) or magnetic resonance (MR) imaging (22–28). All patients were followed for the recurrence of HCCs after RF ablation for a median of 9.7 months (range, 2.0–30.1 mo) at our institution with US every 3 months and CT or MR imaging every 6 months until March 2012. Regular monitoring of serum tumor markers (α -fetoprotein, *Leus culinaris* agglutinin-reactive fraction of α -fetoprotein, and des- γ -carboxy prothrombin) was performed every 3 months. If an increase in tumor marker levels was detected, an additional imaging examination (usually CT or MR imaging) was performed to check for HCC recurrence.

The entire protocol was approved by the institutional ethics committee and was performed in compliance with the Declaration of Helsinki. Informed consent to treatment and participation in the study was obtained in writing from all subjects.

Statistical Analyses

Continuous variables are expressed as mean \pm standard deviation or as median and range. Categorical variables are expressed by using absolute numbers and percentages. The JMP statistical software package (version 4.0; SAS, Cary, North Carolina) was used for all statistical analyses.

RESULTS

In Vitro Experiment: Sodium Hyaluronate Temperature Determination

The temperature of the sodium hyaluronate solution layer was monitored during the heating of the egg white by an RF electrode with a 3-cm exposed tip. The egg white was heated and coagulated (Fig 1). The temperature of the egg white, which was measured at the tip of the RF electrode that was placed in the egg white layer, increased to a maximum of 86°C at 5 minutes after heating was initiated. The procedure was completed in 8 minutes with the coagulation of the egg white. The temperature of the sodium hyaluronate solution increased 2 minutes after the heating was initiated, reached the maximum temperature of 41.3°C at 6 minutes, and remained constant until the end of the procedure.

Phase I Study: Safety of Intraperitoneal Sodium Hyaluronate Injection

No difficulties were encountered while injecting the sodium hyaluronate solution via the 21-gauge needle. Based on the real-time US observation, the sodium hyaluronate solution created a layer (emitting hyperechoic and hypoechoic signals) that maintained a space between the abdominal wall and liver surface until 2 hours after the injection. The layer was not detectable by US on the following morning, which was approximately 15–18 hours after the injection.

None of the patients reported any symptoms, such as fever or abdominal pain, during or after the injection of the sodium hyaluronate solution. Table 1 presents the WBC and CRP results obtained before and 3 days after the injection. No increase in WBC or CRP values that would indicate marked inflammation was observed in any patient regardless of the dose of sodium hyaluronate solution injected. In addition, no findings suggestive of ileus were observed based on abdominal US.

RF Ablation of HCC with Sodium Hyaluronate Solution on the Liver Surface

Table 2 displays the characteristics of the patients and HCC tumors. The treated HCCs were recurrent in 75% of

Table 1. Demographic Details of Peritoneal Injection of Sodium Hyaluronate Solution (N = 6)

Pt. No./Age (y)/Sex	Dose Injected (mL)	WBC Count (/ μ L)		CRP (mg/dL)	
		Baseline	After Injection*	Baseline	After Injection*
1/64/F	5	3,710	3,970	0.06	0.58
2/74/M	5	4,340	3,540	0.69	2.26
3/78/M	10	4,260	4,320	0.14	0.77
4/71/M	10	7,180	6,780	0.12	0.63
5/64/M	20	6,240	6,280	0.25	1.96
6/64/F	20	2,550	3,150	0.06	0.03

CRP = C-reactive protein, WBC = white blood cell.

* Tested 3 d after injection of sodium hyaluronate solution.

patients. Tumors were smaller than 3 cm in all cases. All tumors were located on the liver surface in various sections of the liver except for segments I and VIII. The HCCs were located adjacent to the gallbladder in three patients, the gastrointestinal tract in one patient, and the right kidney in one patient based on US imaging. HCC thermal ablation was performed for 8 minutes with an electrode with a 2-cm exposed tip in 19 patients and for 12 minutes with an electrode with a 3-cm exposed tip in nine patients. None of the patients required a prolonged duration of thermal ablation. In 23 of 28 patients, the proximal end of the exposed metallic tip was located within the sodium hyaluronate solution layer above the liver surface rather than in the tumor or liver tissue.

During the RF ablation procedure, the sodium hyaluronate solution layer on the liver surface did not flow outside of the injection area (Fig 2). No changes in the thickness or in the real-time US appearance of the sodium hyaluronate layer were observed throughout the RF ablation procedure. Based on the clinical evaluations and laboratory tests, no patients experienced clinically significant burn injuries of the abdominal wall or other organs, including those patients who underwent RF ablation for HCCs that were adjacent to the gallbladder (Fig 3) or gastrointestinal tract (Fig E1, available online at www.jvir.org). Based on the imaging examinations, the HCCs were ablated and necrotized with sufficient margins with only one session of RF ablation in all cases (Figs E1 and E2, available online at www.jvir.org). Local recurrence was observed in one of 28 patients (3.6%) during a follow-up of 30.1 months after treatment. The time interval between RF ablation and recurrence was 14.8 months. No patients experienced tumor seeding after RF ablation.

DISCUSSION

The injection of sodium hyaluronate solution into the human body is performed in clinical practice (including intraarticular injections, intralenticular injections, and submucosal injections in the gastrointestinal tract), and the safety of the use of this material in the human body has been established (14–20). In the United States, the use of sodium hyaluronate solution has been approved by the

Table 2. Characteristics of Patients and HCC Tumors

Detail	Value
Age (y)	
Mean \pm SD	70.8 \pm 6.5
Range	58–83
Sex	
Male	23 (82.1)
Female	5 (17.9)
Etiology	
HBV	4 (14.3)
HCV	21 (75.0)
Non-HBV/non-HCV	3 (10.7)
ALT (IU/L)	52.6 \pm 38.7
Platelet count ($\times 10^3$ /mL)	120 \pm 52
Prothrombin (%)	82.5 \pm 14.2
AFP (ng/mL)	
Median	9.8
Range	0.6–521.7
DCP (mAU/mL)	
Median	101.0
Range	6.0–763.0
History of HCC	
Primary	7 (25.0)
Recurrence	21 (75.0)
Tumor location	
Segment II	2 (7.2)
Segment III	6 (21.4)
Segment IV	2 (7.2)
Segment V	7 (25.0)
Segment VI	9 (32.0)
Segment VII	2 (7.2)
Tumor size (mm)	
Mean \pm SD	14.8 \pm 4.8
Range	8.0–26.0
Exposed electrode tip length	
2 cm	19 (67.9)
3 cm	9 (32.1)

AFP = α -fetoprotein, ALT = alanine aminotransferase, DCP = des- γ -carboxy prothrombin, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, SD = standard deviation.

Values presented as means \pm SD where applicable. Values in parentheses are percentages.




Figure 2. RF ablation of HCC (A) located on the liver surface (B) with the injection of a sodium hyaluronate solution onto the liver surface (C). (a) Plain US before injection of sodium hyaluronate solution. (b) Plain US after injection of sodium hyaluronate solution. (c) Evaluation of the treatment response by contrast-enhanced US. The shape of the ablated area (D) was oval instead of round.

Food and Drug Administration for intraarticular injections (Supartz; Smith and Nephew, London, United Kingdom). Although the intraperitoneal injection of sodium hyaluronate is not approved by the Food and Drug Administration, a material containing sodium hyaluronate (Septrafilm; Genzyme, Framingham, Massachusetts) has been approved to be placed into the peritoneum for the prevention of intraperitoneal adhesions. A previous study in animals (29) investigated the concentration of carbon 14-labeled sodium hyaluronate in the plasma, spleen, liver, adrenal gland, fat, expired air, and urine after an intraperitoneal injection. According to this study (29), sodium hyaluronate is absorbed into the blood, and the plasma concentration of sodium hyaluronate peaks 16 hours after injection. The plasma sodium hyaluronate is metabolized mainly in the liver and is excreted into the expired air as CO₂ and into the urine as N-acetyl-D-glucosamine or D-glucosamine until 120 hours after administration. Another study in animals (30) investigated the effects of intravenous injection of sodium hyaluronate on respiration, blood pressure, heart rate, and blood flow, and revealed no changes after the intravenous injection. Because sodium hyaluronate dissolves into the blood (29,30), the inadvertent injection of this solution into a blood vessel would not pose a potential risk for embolization.

The present *in vitro* experiment to determine the temperature of the sodium hyaluronate solution revealed that the thermal ablative procedure did not increase the temperature of the sodium hyaluronate solution to a degree that could cause burn injuries. A previous study (31) also reported that viscoelastic substances, including sodium hyaluronate, protect against the temperature increase that occurs during phacoemulsification for cataract surgeries. In addition, a phase I study of the safety of the intraperitoneal injection of a sodium hyaluronate solution did not reveal any marked intraperitoneal inflammation or adhesions. Indeed, a material containing sodium hyaluronate (Septrafilm; Genzyme) is routinely placed into the peritoneum to prevent the formation of adhesions; in addition, an animal study (32) demonstrated that a cross-linked hyaluronate hydrogel reduces the reformation of postsurgical adhesions.

In the present study, the sodium hyaluronate solution separated the liver surface from the abdominal wall or other organs adjacent to the HCC for 2 hours. This separation prevented burn injuries to the adjacent structures and allowed completion of the thermal ablation of HCCs located on the liver surface. Based on the evaluation of the treatment response, each HCC was sufficiently ablated and necrotized by one session of RF ablation. Because the shape of the area necrotized by thermal ablation is usually oval (especially with the Cool-tip needle), some parts of an HCC could have remained unablated if the exposed metallic tip was completely inserted into the HCC or the adjacent liver tissue to prevent a burn injury to the abdominal wall (Fig 4a). By contrast, with a sodium hyaluronate layer on the liver surface, it would be possible to perform the thermal ablation with the proximal end of the exposed tip placed outside of the liver, thereby ablating the entire HCC tumor with a sufficient margin while preventing burn injuries to the adjacent structures (Fig 4b).

Based on the evaluation of treatment response and follow-up, all HCCs were successfully treated in one session, which yielded adequate margins. In addition, the local recurrence rate of HCCs after treatment was comparable to that of all HCCs treated by RF ablation, including those that are not located close to the liver surface (33–35), and was also comparable to that of HCCs located on the liver surface and treated with RF ablation via laparoscopic approach or with the creation of artificial ascites (9,11,36). Based on these results, the placement of a sodium hyaluronate solution onto the liver surface might be an additional supportive procedure for RF ablation of HCCs located on the liver surface.

There are limitations to the present study. First, the results are preliminary and based on a small series of patients. Larger studies would be necessary to confirm the safety and efficacy of this procedure. In addition, the assessment of the intraperitoneal inflammation and adhesion associated with the intraperitoneal injection of sodium hyaluronate, as well as the assessment of the burn injuries




Figure 3. RF ablation of HCC (A, dotted arrow) located on the liver surface and adjacent to the gallbladder (B) with the injection of a sodium hyaluronate solution. (a) Before the injection of the sodium hyaluronate solution, the gallbladder was adjacent to the HCC tumor. (b) The injection of sodium hyaluronate solution created a separation (C) between the HCC tumor and the gallbladder. (c) Insertion of RF ablation needle (D). (d) Thermal ablation with bubbles (E).




Figure 4. Schematic representation of RF ablation of HCC located on the liver surface. (a) The margin around the HCC was small in certain parts if the exposed metallic tip was completely inserted into the tumor or the adjacent liver tissue to prevent burn injuries to the abdominal wall. (b) Thermal ablation could be performed with the proximal end of the exposed tip placed outside of the liver and within the sodium hyaluronate layer, allowing the safe ablation of the entire HCC and yielding a uniform margin.

associated with RF ablation, might not have been sufficient; these assessments were based on clinical symptoms and laboratory data. It was not possible to investigate the occurrence of intraperitoneal inflammation, adhesions, or burn injuries directly, and further evaluations would be required to assess the intraperitoneal complications

associated with RF ablation and intraperitoneal injection of a sodium hyaluronate solution. US images of the injected sodium hyaluronate layer revealed a mixture of hyperechoic and hypoechoic signals that may cause a reduction in the quality of the HCC visualization. This phenomenon could be caused by microbubbles in the

sodium hyaluronate solution that may disturb the permeability of the US waves. The development of sodium hyaluronate solutions that produce no microbubbles might resolve this problem. In addition, the placement of sodium hyaluronate solution onto the liver surface distal to the body surface or onto the liver surface in patients with ascites was not fully attempted. Therefore, further attempts to apply this material in various patients and to various sites on the liver surface will be necessary to establish this method as a supportive procedure for RF ablation to treat HCCs located close to the liver surface.

In conclusion, the placement of a sodium hyaluronate solution onto the liver surface appears to be a safe and effective supportive procedure for RF ablation of HCCs located on or close to the liver surface. Use of a sodium hyaluronate solution would allow the entire HCC to be necrotized while preventing burn injuries to the adjacent abdominal wall or organs.

REFERENCES

- Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. *AJR Am J Roentogenol* 1996; 167:759–768.
- Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. *Radiology* 1999; 210:655–661.
- Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. *Radiology* 2000; 214:761–768.
- Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. *Br J Surg* 2002; 89:1206–1222.
- Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. *Radiology* 2003; 226:441–451.
- Chopra S, Dodd GD III, Chanin MP, Chintapalli KN. Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. *AJR Am J Roentogenol* 2003; 180:697–701.
- Podnos YD, Henry G, Ortiz JA, et al. Laparoscopic ultrasound with radiofrequency ablation in cirrhotic patients with hepatocellular carcinoma: technique and technical considerations. *Am Surg* 2001; 67:1181–1184.
- Asahina Y, Nakanishi H, Izumi N. Laparoscopic radiofrequency ablation for hepatocellular carcinoma. *Dig Endosc* 2009; 21:67–72.
- Hirooka M, Kisaka Y, Uehara T, et al. Efficacy of laparoscopic radio-frequency ablation for hepatocellular carcinoma compared to percutaneous radiofrequency ablation with artificial ascites. *Dig Endosc* 2009; 21:82–86.
- Ohmoto K, Yamamoto S. Percutaneous microwave coagulation therapy using artificial ascites. *AJR Am J Roentogenol* 2001; 176:817–818.
- Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. *Br J Surg* 2006; 93:1277–1282.
- Hedenstierna G, Larsson A. Influence of abdominal pressure on respiratory and abdominal organ function. *Curr Opin Crit Care* 2012; 18:80–85.
- Malbrain ML, Ameloot K, Gillbert C, Cheatham ML. Cardiopulmonary monitoring in intra-abdominal hypertension. *Am Surg* 2011; 77(suppl):S23–S30.
- Rydell N, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. *Clin Orthop Relat Res* 1971; 80:25–32.
- Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. *Pathol Biol (Paris)* 1974; 22:731–736.
- Miller D, O'Connor P, Williams J. Use of Na-Hyaluronate during intraocular lens implantation in rabbits. *Ophthalm Surg* 1977; 8:58–61.
- Yamamoto H, Koiwai H, Yube T, et al. A successful single-step endoscopic resection of a 40 millimeter flat-lifted tumor in the rectum: endoscopic mucosal resection using sodium hyaluronate. *Gastrointest Endosc* 1999; 50:701–704.
- Yamamoto H, Kawata H, Sunada K, et al. Success rate of curative endoscopic mucosal resection with circumferential mucosal injection assisted by submucosal injection of sodium hyaluronate. *Gastrointest Endosc* 2002; 56:507–512.
- Yamamoto H, Yahagi N, Oyama T, et al. Usefulness and safety of 0.4% sodium hyaluronate solution as a submucosal fluid “cushion” in endoscopic resection for gastric tumor: a prospective multicenter trial. *Gastrointest Endosc* 2008; 67:830–839.
- Hirasaki S, Kozu T, Yamamoto H, et al. Usefulness and safety of 0.4% sodium hyaluronate solution as a submucosal fluid “cushion” for endoscopic resection of colorectal mucosal neoplasms: a prospective multicenter open-label trial. *BMC Gastroenterol* 2009; 9:1.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; 42:1208–1236.
- Ebara M, Kita K, Sugiura N, et al. Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT. *Radiology* 1995; 195:371–377.
- Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T. Post-treatment imaging of liver tumours. *Cancer Imaging* 2007; 7:S28–36.
- Gervais DA, Kalva S, Thabet A. Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. *Abdom Imaging* 2009; 34:593–609.
- Tokunaga S, Koda M, Matono T, et al. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. *Br J Radiol* 2012; 85:745–752.
- Kim CK, Choi D, Lim HK, et al. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. *Eur J Radiol* 2005; 56:66–73.
- Pompili M, Riccardi L, Covino M, et al. Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. *Liver Int* 2005; 25:954–961.
- Zhou P, Kudo M, Minami Y, et al. What is the best time to evaluate treatment response after radiofrequency ablation of hepatocellular carcinoma using contrast-enhanced sonography? *Oncology* 2007; 72(suppl):S92–S97.
- Mizuno S, Tominaga A, Sakamoto T, Tokuyasu K. Biological fate of sodium hyaluronate (SPH) (4). Studies on absorption, distribution, metabolism and excretion of ¹⁴C-SPH in rat after intraperitoneal, subcutaneous, and intramuscular administration. *Oyo Yakuri* 1987; 33:849–857.
- Miyazaki K, Yamaguchi T, Senoo N, Tokiwa T. General pharmacological studies of sodium hyaluronate (SPH). *Oyo Yakuri* 1984; 28:1137–1149.
- Jurowski P, Gos R, Kusmierczyk J, Owczarek G, Gralewicz G. Quantitative thermographic analysis of viscoelastic substances in an experimental study in rabbits. *J Cataract Refract Surg* 2006; 32:137–140.
- Osada H, Takahashi K, Fujii TK, Tsunoda I, Satoh K. The effect of cross-linked hyaluronate hydrogel on the reduction of post-surgical adhesion reformation in rabbits. *J Int Med Res* 1999; 27:233–241.
- Nishikawa H, Inuzuka T, Takeda H, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. *J Gastroenterol* 2011; 46:1418–1426.
- Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. *Am J Gastroenterol* 2012; 107:567–577.
- Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. *J Gastroenterol Hepatol* 2012; 27:51–58.
- Uehara T, Hirooka M, Ishida K, et al. Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. *J Gastroenterol* 2007; 42:306–311.




Figure E1. Radiofrequency (RF) ablation of a hepatocellular carcinoma (HCC; A) located on the liver surface and adjacent to the intestinal tract (B). Computed tomography before (a) and after (b) RF ablation. The HCC located on the edge of the liver was necrotized completely (C). (c) Plain ultrasound (US) before RF ablation. (d) Contrast-enhanced US after RF ablation shows necrotizing area (C).





Figure E2. Dynamic magnetic resonance imaging results of RF ablation of HCC located on the liver surface. (a) Before RF ablation, an enhancing HCC tumor (A) was observed. (b) After RF ablation, the HCC and adjacent liver tissue were ablated in an oval shape (B).



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy

Hidenori Toyoda^{1,*}, Takashi Kumada¹, Toshifumi Tada¹, Takuro Niinomi¹, Takanori Ito¹, Yuji Kaneoka², Atsuyuki Maeda²

¹Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan; ²Department of Surgery, Ogaki Municipal Hospital, Ogaki, Japan

Background & Aims: Previous studies reported that the combination of three tumor markers for hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), *Lens culinaris* agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP), has the ability to discriminate survival among patients with HCC. In those studies, however, the study population included all patients with various treatment modalities, and tumor markers were measured only before treatment. We investigated the prognostic value of a combination of these tumor markers for HCC, measured before and after treatment, on survival and recurrence in patients treated with hepatectomy.

Methods: A total of 173 patients who underwent hepatectomy for primary, non-recurrent HCC were analyzed. Tumor characteristics, postoperative survival, and recurrence rates were compared according to the number of elevated tumor markers measured before and after treatment.

Results: The correlation between the number of elevated tumor markers before treatment and tumor size, rate of portal vein invasion, and tumor differentiation, respectively, was stronger than that between the number of elevated tumor markers after treatment. In contrast, the number of elevated tumor markers after treatment displayed an excellent ability to discriminate post-treatment survival and recurrence rates compared to that before treatment, and was an independent factor associated with survival and recurrence in multivariate analysis.

Conclusions: The combination of tumor markers measured after hepatectomy has a better discriminatory ability for postoperative survival and recurrence in HCC patients treated with hepatectomy in comparison to the combination of tumor markers measured before treatment.

© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords: Hepatocellular carcinoma; Tumor markers; Survival; Recurrence; Curative hepatectomy.

Received 5 April 2012; received in revised form 11 July 2012; accepted 11 July 2012; available online 20 July 2012

* Corresponding author. Address: Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. Tel.: +81 584 81 3341; fax: +81 584 75 5715.

E-mail address: hmtoyoda@spice.ocn.ne.jp (H. Toyoda).

Abbreviations: HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; AFP-L3, *Lens culinaris* agglutinin-reactive fraction of alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; PIVKA-II, vitamin K absence/antagonist-II; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer-related death [1,2]. In Japan, HCC currently represents the third and fifth most common cause of death from cancer in men and women, respectively, [3]. Presently, three tumor markers specific for HCC are used clinically: alpha-fetoprotein (AFP), *Lens culinaris* agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP), which is also known as protein induced by vitamin K absence/antagonist-II (PIVKA-II). The clinical utility of these tumor markers for detection and diagnosis of HCC, for evaluation of tumor progression, and for determination of prognosis has been reported [4-7]. In addition, the combination of these three tumor markers has been indicated as a useful predictor of patient outcome. We previously reported the prognostic significance of the combination of three tumor markers measured at diagnosis on the survival of all patients with HCC [8]. An increase in the number of elevated tumor markers, consisting of AFP, AFP-L3, and DCP, was clearly associated with a decreased survival rate in patients with HCC. In addition, an increase in the number of elevated tumor markers was well correlated with indicators of HCC progression, including the size and number of tumors, and the rate of portal vein invasion. More recently, Kim *et al.* have reported less progression of HCC without the elevation of AFP and DCP, with higher survival rates [9].

However, in these studies, all patients with HCC who underwent various treatment modalities had been included into the study. In addition, the levels of tumor markers were measured at diagnosis and before treatment. The predictive ability of post-treatment vs. pretreatment tumor markers has not been evaluated and compared. In the present study, we measured the levels of these three tumor markers both before and after treatment, in patients who underwent hepatectomy with curative intent. We analyzed their relationship with tumor progression, survival, and recurrence after treatment.

Materials and methods

Patients

A total of 828 patients were diagnosed with primary, non-recurrent HCC, between January 2001 and December 2010 at Ogaki Municipal Hospital. Of these



Research Article

patients, 264 were treated with hepatectomy. Stored serum samples were available for measurement of the levels of three tumor markers, AFP, AFP-L3, and DCP, before and after hepatectomy in 173 patients. Decisions regarding each patient's course of treatment were made based on the treatment guidelines for HCC in Japan [10]. Anatomical hepatectomy was performed in all 173 patients. HCC tumors were resected with ample margins and enucleation of tumors without adequate margins was not performed. The diagnosis of HCC was confirmed by pathologic examination of resected specimens.

One month after hepatectomy, all patients underwent computed tomography (CT) examination of thorax and abdomen to confirm the absence of residual HCC. All patients were followed-up, for a median of 34.2 months (range, 4.3–122.8 months) until March 2012 at our institution, with ultrasound (US) and CT, or US and magnetic resonance imaging (MRI) every 3–6 months. Regular monitoring of the three tumor markers was performed every 3 months. When an elevation of tumor markers was detected, additional imaging examinations (usually CT or MRI) were performed to check for recurrence. If the presence of recurrence was confirmed, patients underwent treatment for recurrent HCC based on treatment guidelines.

The entire protocol was approved by the hospital institutional review board and carried out in compliance with the Helsinki Declaration.

Measurement of hepatocellular carcinoma tumor markers

Pretreatment tumor markers were measured within 1 week before hepatectomy. Post-treatment tumor markers were measured in the serum sample obtained at the first visit, between 1 and 2 months after hepatectomy. The reported half-lives of AFP and AFP-L3 are 4 days [11] and the half-life of DCP is 60 h [12]. Therefore, the values of post-treatment tumor markers were not influenced by pretreatment tumor marker elevations. Measurements of AFP, AFP-L3, and DCP levels were performed with a microchip capillary electrophoresis and liquid-phase binding assay on the μ TASWako i30 auto analyzer (Wako Pure Chemical Industries, Ltd., Osaka, Japan) [13]. The cut-off value of 20 ng/ml was used to establish positivity for AFP, as proposed by Oka *et al.* and Koda *et al.* [14,15]. The cut-off value used to establish positivity for AFP-L3 was 5%, based on our previous study [16]. The cut-off value used to establish positivity for DCP was 40 mAU/ml, as proposed by Okuda *et al.* [17]. The number of tumor markers above the cut-off values was calculated as the number of elevated tumor markers, and survival and recurrence rates were analyzed according to the number of elevated tumor markers.

Statistical analyses

Differences in percentages between groups were analyzed with the Chi-square test. Differences in mean quantitative values were analyzed with the Mann-Whitney *U* test. Changes in percentages and quantitative values with the increase in the number of elevated tumor markers were analyzed with the Cochran-Armitage test and the Jonckheere-Terpstra test, respectively. Receiver-operating characteristics analyses were performed to determine the cut-offs of the number of elevated tumor markers in order to evaluate the accuracy of prediction of 1-, 3-, and 5-year survivals and recurrences and compare them with the accuracy of elevation of each tumor marker. The date of hepatectomy was defined as time zero for the calculation of survival and recurrence rates. In the analysis of survival rates, patients who died were non-censored and patients who survived were censored. In the analysis of recurrence rates, patients in whom HCC recurred were non-censored, and those in whom HCC did not recur were censored. The Kaplan-Meier method [18] was used to calculate survival and recurrence rates, and the log-rank test [19] was used to analyze differences in survival and recurrence.

The Cox proportional hazards model [20] was used for multivariate analyses of factors related to survival and recurrence. Variables analyzed included age, sex, Child-Pugh class (A/B), tumor size, number of tumors, differentiation of HCC (well-moderately or poorly), growth pattern (expansive growth/infiltrative growth), macroscopic and microscopic portal vein invasion (absent/present), and number of elevated tumor markers (zero, one, two, or three). Data analyses were performed using JMP statistical software, version 6.0 (Macintosh version; SAS Institute, Cary, NC, USA). All *p* values were derived from two-tailed tests, with *p* < 0.05 considered to indicate statistical significance.

Results

Characteristics of patients and hepatocellular carcinoma

Table 1 summarizes the pretreatment characteristics of the study patients. This population comprised 136 males and 37 females

with a mean age of 67.0 ± 8.8 years. Most (95.4%) patients belonged to Child-Pugh class [21] A. Multiple tumors were present in 16.8% of patients. HCC was well differentiated in 37.0% and portal vein invasion was observed in 23.1% of patients, based on the pathologic examination of resected HCC specimens. Pretreatment AFP, AFP-L3, and DCP were above the specified cut-off levels in 34.7%, 44.5%, and 52.0% of patients, respectively.

Clinical and pathologic characteristics of hepatocellular carcinoma based on a combination of three tumor markers measured before and after hepatectomy

At pretreatment, there were 47 (27.2%) patients with no elevated tumor markers and 57 (32.9%) patients with one, 38 (22.0%) with two, and 31 (17.9%) with three elevated tumor markers. After hepatectomy, 75 (43.3%) patients had no elevated tumor markers, 70 (40.5%) patients had one, 24 (13.9%) had two, and 4 (2.3%) had three elevated tumor markers. Tables 2 shows pretreatment clinical characteristics and pathologic characteristics of the resected HCC specimens according to the number of elevated tumor markers measured before and after hepatectomy. An increase in tumor size was associated with an increase in the number of elevated tumor markers before treatment (*p* < 0.0001). This gradual increase in tumor size according to the number of elevated tumor markers was not observed with post-treatment values (*p* = 0.5836). On pathologic examination, there was a gradual decrease in the rate of well-differentiated HCC (*p* < 0.0001) and of HCC with expansive growth (*p* = 0.0010), and a gradual increase in the rate of HCC with portal vein invasion (*p* < 0.0001) based on the number of elevated tumor markers before treatment. These are not significant when compared with postoperative values (the rate of well-differentiated HCC, *p* = 0.3962, of HCC with expansive growth, *p* = 0.3036, and the rate of HCC with portal vein invasion, *p* = 0.0898).

Post-operative survival rates based on the combination of three tumor markers measured before and after hepatectomy

The survival rates were compared by the elevation of each tumor marker. By comparing tumor markers measured before treatment, we found significant differences in survival rates by elevated AFP, and AFP-L3 levels, but not DCP (Supplementary Fig. 1). By comparing tumor markers measured after treatment, survival rates were significantly lower in patients with elevated AFP, AFP-L3, and DCP levels, respectively (Supplementary Fig. 2). We determined the survival rates of patients after hepatectomy as a function of the number of elevated tumor markers before and after hepatectomy (Fig. 1). The number of elevated tumor markers after treatment provided a better discrimination of survival rates than the number of elevated tumor markers before treatment. The survival rates were higher in patients without elevated tumor markers after treatment, followed by patients with one, two, and three elevated tumor markers, in this order.

We next compared the accuracy of death prediction between each individual tumor marker and the combination of the three (Supplementary Table 1). Higher accuracy in predicting death within 1, 3, and 5 year(s), respectively, was found by combining the three markers than by each individual marker alone.

In multivariate analysis, the number of elevated tumor markers was not associated with specific survival after hepatectomy, when tumor markers measured before treatment were used (Supplementary Table 2). In contrast, it was an independent

Table 1. Characteristics of the study patients (n = 173).

Age (yr); (range)	67.0 ± 8.8 (21-83)
Sex (female/male)	37 (21.4)/136 (78.6)
Etiology (HBV/HCV/HBV+HCV/non-HBV, non-HCV)	29 (16.8)/116 (67.0)/2 (1.2)/26 (15.0)
Child-Pugh class (A/B)	165 (95.4)/8 (4.6)
Albumin (g/dl)	4.02 ± 0.42
Total bilirubin (mg/dl)	0.78 ± 0.34
15-min retention rate of ICG (%)	15.4 ± 7.4
Prothrombin (%)	92.7 ± 14.3
Platelet (x10 ³ /ml)	144 ± 71
Tumor size (cm); (range)	3.28 ± 2.59 (0.8-16.4)
Number of tumors (n); (range)	1.24 ± 0.56 (1-3)
Single/multiple	144 (83.2)/29 (16.8)
Macroscopic portal vein invasion (absent/present)*	167 (96.5)/6 (3.5)
Microscopic portal vein invasion (absent/present)	133 (76.9)/40 (23.1)
Differentiation (well-/moderately or poorly)	64 (37.0)/109 (63.0)
Growth pattern (expansive growth/infiltrative growth)	151 (87.3)/22 (12.7)
AFP (ng/ml); median (range)	10.9 (0.8-27,242.8)
≥20 ng/ml/<20 ng/ml	60 (34.7)/113 (65.3)
AFP-L3 (%); median (range)	3.9 (0.0-89.7)
≥5%/<5%	77 (44.5)/96 (55.5)
DCP (mAU/ml); median (range)	43.0 (5.0-60,030.0)
≥40 mAU/ml/<40 mAU/ml	90 (52.0)/83 (48.0)

Values are mean ± SD, unless otherwise indicated.

Percentages are given in parentheses, unless otherwise indicated.

HBV, hepatitis B virus; HCV, hepatitis C virus; ICG, indocyanine green test; AFP, alpha-fetoprotein; AFP-L3, *Lens culinaris* agglutinin-reactive AFP; DCP, des-gamma-carboxy prothrombin.

*Evaluated based on imaging findings.

factor associated with survival when the number of elevated tumor markers was replaced by those measured after treatment (Table 3).

Post-treatment recurrence rates based on the combination of three tumor markers measured before and after hepatectomy

The rates of recurrence were compared by the elevation of each tumor marker. In comparisons of tumor markers measured before treatment, we did not find significant differences in recurrence rates by the elevation of AFP and DCP (Supplementary Fig. 3). In comparisons of tumor markers measured after treatment, recurrence rates were significantly higher in patients with elevated AFP, AFP-L3, and DCP levels, respectively (Supplementary Fig. 4). We determined the rates of recurrence in patients, after hepatectomy with curative intent, based on the number of elevated tumor markers before and after hepatectomy (Fig. 2). We did not find any difference in the recurrence rates based on the number of elevated tumor markers measured before treatment. In contrast, higher recurrence rates were associated with an increasing number of elevated tumor markers measured after treatment. Moreover, higher accuracy in prediction of recurrence within 1, 3, and 5 year(s), was found with the combination of these three markers than with each individual marker alone (Supplementary Table 3).

In multivariate analysis, the number of elevated tumor markers was not associated with recurrence after hepatectomy, when tumor markers measured before treatment were used

(Supplementary Table 4). In contrast, it was an independent factor associated with recurrence when the number of elevated tumor markers was replaced by those measured after treatment (Table 4).

Discussion

In the present study, we investigated the significance of a combination of three tumor markers for HCC (AFP, AFP-L3, and DCP) measured after treatment vs. before treatment, in predicting outcome in patients undergoing hepatectomy with curative intent. Our results demonstrated that the number of elevated tumor markers after treatment had a better discriminatory ability for both survival and recurrence rates after hepatectomy. A gradual decrease in survival rates and an increase in recurrence rates were observed as the number of post-treatment elevated tumor markers increased.

In our previous study of 685 patients with HCC [8], the number of elevated tumor markers measured before treatment was well associated with the progression of HCC and survival rates. In contrast, in the present study, the number of elevated pretreatment tumor markers did not predict survival and recurrence rates, although it was associated with the progression of HCC. This could be due to the fact that the patients analyzed in our previous study underwent various types of treatment according to HCC progression and liver function, while in the present study we focused on HCC patients who underwent hepatectomy with

Research Article

Table 2. Clinical characteristics of patients with HCC based on the number of positive tumor markers measured (A) before hepatectomy and (B) after hepatectomy (n = 173).

	Number of positive tumor markers before treatment			
	0 (n = 47)	1 (n = 57)	2 (n = 38)	3 (n = 31)
Age (yr)	67.1 ± 7.6	67.8 ± 8.0	68.2 ± 8.4	64.2 ± 12.0
Sex (female/male)	6 (12.8)/41 (87.2)	16 (28.1)/41 (71.9)	10 (26.3)/28 (73.7)	5 (16.1)/26 (83.9)
Child-Pugh class (A/B)	46 (97.9)/1 (2.1)	55 (96.5)/2 (3.5)	35 (92.1)/3 (7.9)	29 (93.5)/2 (6.5)
Albumin (g/dl)	4.03 ± 0.32	4.04 ± 0.45	3.96 ± 0.48	4.06 ± 0.43
Total bilirubin (mg/dl)	0.75 ± 0.34	0.77 ± 0.28	0.81 ± 0.39	0.80 ± 0.36
15-min retention rate of ICG (%)	14.9 ± 6.2	16.6 ± 9.1	16.1 ± 6.7	13.1 ± 5.6
Prothrombin (%)	93.1 ± 13.9	90.8 ± 15.6	91.3 ± 11.9	97.2 ± 14.9
Platelet (x10 ³ /ml)	149 ± 89	140 ± 62	138 ± 70	150 ± 59
Tumor size (cm) ¹	2.25 ± 1.09	2.96 ± 2.02	3.75 ± 2.88	4.87 ± 3.74
Number of tumors (single/multiple)	40 (85.1)/7 (14.9)	50 (87.7)/7 (12.3)	30 (78.9)/8 (21.1)	24 (77.4)/7 (22.6)
Differentiation (well-/moderately or poorly) ²	26 (55.3)/21 (44.7)	27 (47.4)/30 (52.6)	9 (23.7)/29 (76.3)	2 (6.5)/29 (93.5)
Growth pattern (expansive/infiltrative) ³	44 (93.6)/3 (6.4)	53 (93.0)/4 (7.0)	34 (89.5)/4 (10.5)	20 (64.5)/11 (35.5)
Capsular formation (absent/present)*	24 (54.5)/20 (45.5)	25 (47.2)/28 (52.8)	10 (29.4)/24 (70.6)	3 (15.0)/17 (85.0)
Capsular infiltration (absent/present)**	11 (55.0)/9 (45.0)	15 (53.6)/13 (46.4)	8 (33.3)/16 (66.7)	6 (35.3)/11 (64.7)
Portal vein invasion (absent/present)*** ⁴	44 (93.6)/3 (6.4)	52 (91.2)/5 (8.8)	27 (71.1)/11 (28.9)	10 (32.3)/21 (67.7)

	Number of positive tumor markers after treatment			
	0 (n = 75)	1 (n = 70)	2 (n = 24)	3 (n = 4)
Age (yr)	67.7 ± 9.3	66.8 ± 7.9	65.1 ± 10.3	72.0 ± 4.5
Sex (female/male)	14 (18.7)/61 (81.3)	17 (24.3)/53 (75.7)	6 (25.0)/18 (75.0)	0/4 (100.0)
Child-Pugh class (A/B)	73 (97.3)/2 (2.7)	64 (91.4)/6 (8.6)	24 (100.0)/0	4 (100.0)/0
Albumin (g/dl)	4.10 ± 0.41	3.99 ± 0.44	3.88 ± 0.35	4.13 ± 0.39
Total bilirubin (mg/dl)	0.82 ± 0.36	0.73 ± 0.31	0.74 ± 0.31	0.80 ± 0.35
15-min retention rate of ICG (%)	14.6 ± 6.2	16.3 ± 8.8	15.7 ± 6.4	15.5 ± 4.6
Prothrombin (%)	94.4 ± 13.3	90.4 ± 16.1	93.7 ± 12.8	94.8 ± 6.2
Platelet (x10 ³ /ml)	157 ± 87	136 ± 58	121 ± 52	161 ± 39
Tumor size (cm)	3.33 ± 2.58	2.86 ± 1.93	3.71 ± 3.11	6.90 ± 6.44
Number of tumors (single/multiple)	63 (84.0)/12 (16.0)	61 (87.1)/9 (12.9)	18 (75.0)/6 (25.0)	2 (50.0)/2 (50.0)
Differentiation (well-/moderately or poorly)	30 (40.0)/45 (60.0)	25 (35.7)/45 (64.3)	9 (37.5)/15 (62.5)	0/4 (100.0)
Growth pattern (expansive/infiltrative)	66 (88.0)/9 (12.0)	64 (91.4)/6 (8.6)	18 (75.0)/6 (25.0)	3 (75.0)/1 (25.0)
Capsular formation (absent/present)*	23 (34.8)/43 (65.2)	33 (51.6)/31 (48.4)	6 (33.3)/12 (66.7)	0/3 (100.0)
Capsular infiltration (absent/present)**	20 (46.5)/23 (53.5)	17 (54.8)/14 (45.2)	3 (25.0)/9 (75.0)	0/3 (100.0)
Portal vein invasion (absent/present)***	59 (78.7)/16 (21.3)	59 (84.3)/11 (15.7)	14 (58.3)/10 (41.7)	1 (25.0)/3 (75.0)

¹p < 0.0001 (Jonckheere–Terpstra test); ^{2,4}p < 0.0001; ³p = 0.0010 (Cochran–Armitage test).
ICG, indocyanine green test.

*Evaluated only in HCC with expansive growth.

**Evaluated only in HCC with capsular formation.

***On pathologic evaluation.

Unless otherwise indicated, values are mean ± SD and percentages are indicated in parentheses.

ICG, indocyanine green test.

curative intent. Recently, Kiriya *et al.* have investigated the utility of the combination of these three tumor markers measured at diagnosis (before treatment) in predicting outcomes in

HCC patients treated with hepatectomy [22]. They have reported that elevation of all three tumor markers (triple positive tumor markers) is associated with invasive tumor growth, and patients




Fig. 1. Survival rates after hepatectomy as a function of the number of elevated tumor markers measured before and after hepatectomy. (A) Survival rates according to the number of elevated tumor markers measured before hepatectomy (zero vs. one, $p = 0.0907$; one vs. two, $p = 0.1542$; two vs. three, $p = 0.8772$). (B) Survival rates according to the number of elevated tumor markers measured after hepatectomy (zero vs. one, $p = 0.0322$; one vs. two, $p = 0.0085$; two vs. three, $p = 0.0006$).

with triple positive tumor markers have significantly lower recurrence-free and disease-specific survival rates after hepatec-

tomy. Their study has included patients who underwent non-anatomical hepatectomy (35.7%). This treatment with insufficient curativity might have increased the impact of triple positive pretreatment tumor markers and associated progression of HCC on the prognosis of patients after hepatectomy. In contrast to their results, we did not find any difference in survival and recurrence rates between patients with triple positive tumor markers and other patients in the pretreatment evaluation, for patients who underwent anatomical hepatectomy. In addition, they failed to find any differences in the rates between patients with one or two positive tumor markers and those without positive tumor markers, measured before treatment. With respect to the post-treatment evaluation in our study, decreased survival rates and increased recurrence rates were observed, not only in patients with elevation of all three tumor markers but also in patients with one or two elevated tumor markers, when compared to those with no elevated tumor markers. Thus, the number of elevated tumor markers after treatment was well associated with prognosis after curative hepatectomy and categorized patients into 4 groups by the likelihood of survival and recurrence.

An increase in tumor size and the rate of portal vein invasion, and a decrease in the rate of well-differentiated HCC and of HCC

Table 3. Univariate and multivariate analyses for factors associated with postoperative survival using a combination of three tumor markers measured after hepatectomy (n = 173).

Factor	Univariate analyses		Multivariate analyses	
	p value	Risk ratio (95% CI)	p value	Risk ratio (95% CI)
Age	0.0518	1.0358 (0.9997-1.0766)	0.1032	1.0320 (0.9939-1.0753)
Sex				
Male		1		
Female	0.3682	0.8371 (0.5350-1.2138)		
Child-Pugh class				
A		1		
B	0.2379	0.6038 (0.6039-1.2951)		
Tumor size	0.0012	1.1625 (1.0671-1.2497)	0.2049	1.0639 (0.9650-1.1651)
Number of tumors	0.0006	2.2953 (1.4681-3.4226)	0.0370	1.7047 (1.0345-2.7230)
Differentiation				
Well-		1		
Moderately/poorly	0.0009	1.7532 (1.2453-2.6068)	0.0554	1.4437 (0.9918-2.1943)
Growth pattern				
Expansive		1		
Infiltrative	0.0142	1.6225 (1.1114-2.2602)	0.3353	1.2306 (0.7984-1.8370)
Macroscopic portal vein invasion				
Absent		1		
Present	0.2168	1.5151 (0.7443-2.5195)		
Microscopic portal vein invasion				
Absent		1		
Present	0.0083	1.5829 (1.1327-2.1604)	0.5730	1.1162 (0.7554-1.6191)
Number of positive tumor markers				
0		1		
1	0.0315	1.4807 (1.0344-2.1980)	0.0194	1.5534 (1.0720-2.3312)
2	0.0004	2.3463 (1.4928-3.6906)	0.0172	1.8241 (1.1157-2.9683)
3	<0.0001	6.0824 (3.0998-10.9708)	0.0018	3.6788 (1.7020-7.3886)

Research Article




Fig. 2. Recurrence rates after hepatectomy as a function of the number of elevated tumor markers measured before and after hepatectomy. (A) Recurrence rates according to the number of elevated tumor markers measured before hepatectomy (zero vs. one, $p = 0.4966$; one vs. two, $p = 0.1756$; two vs. three, $p = 0.6227$). (B) Recurrence rates according to the number of elevated tumor markers measured after hepatectomy (zero vs. one, $p = 0.0352$; one vs. two, $p = 0.0050$; two vs. three, $p < 0.0001$).

with expansive growth were found in association with the number of elevated tumor markers before treatment, as in our previous report [8] and the report by Kiriya *et al.* [22]. These associations lacked with the number of elevated tumor markers after treatment. Although pretreatment elevations of HCC tumor markers, especially AFP-L3 and DCP, have been reported to indicate advanced characteristics of HCC with poor prognosis [23,24], the effects markedly decreased when patients underwent hepatectomy [25]. Hepatectomy appears to effectively treat HCC with high malignant potential associated with a pretreatment elevation of tumor markers, if hepatectomy is performed anatomically with curative intent. Indeed, the number of elevated tumor markers markedly decreased after treatment in patients who underwent hepatectomy compared to patients treated with loco-regional ablative therapies (radiofrequency ablation or ethanol injection) or transcatheter arterial chemoembolization [8]. Therefore, the elevation of tumor markers after hepatectomy may indicate the residual minute HCC cells that cannot be identified during hepatectomy and imaging examination after treatment. Patients in whom all three tumor markers remained positive even after hepatectomy had markedly low survival and high recurrence

Table 4. Univariate and multivariate analyses for factors associated with postoperative recurrence using a combination of three tumor markers measured after hepatectomy (n = 173).

Factor	Univariate analyses		Multivariate analyses	
	p value	Risk ratio (95% CI)	p value	Risk ratio (95% CI)
Age	0.1167	1.0185 (0.9957-1.0437)		
Sex				
Male		1		
Female	0.5384	0.9220 (0.6971-1.1841)		
Child-Pugh class				
A		1		
B	0.7533	1.0701 (0.6675-1.5515)		
Tumor size	<0.0001	1.1745 (1.0994-1.2431)	0.1180	1.0764 (0.9815-1.1826)
Number of tumors	0.0023	1.8096 (1.2539-2.5105)	0.0329	1.5975 (1.0409-2.3558)
Differentiation				
Well-		1		
Moderately/poorly	0.0222	1.2817 (1.0354-1.6045)	0.2196	1.1620 (0.9149-1.4852)
Growth pattern				
Expansive		1		
Infiltrative	0.2978	1.1830 (0.8512-1.5707)		
Macroscopic portal vein invasion				
Absent		1		
Present	0.0123	1.8793 (1.1690-2.7380)	0.1300	1.6593 (0.8519-2.9452)
Microscopic portal vein invasion				
Absent		1		
Present	0.0504	1.3051 (0.9995-1.6620)	0.4978	1.1115 (0.8121-1.4897)
Number of positive tumor markers				
0		1		
1	0.0413	1.2716 (1.0095-1.6088)	0.0069	1.4017 (1.0967-1.8044)
2	0.0001	1.9214 (1.3999-2.5862)	0.0001	2.0143 (1.4590-2.7324)
3	<0.0001	11.8230 (5.5814-25.0773)	<0.0001	8.3969 (3.4707-19.7694)

rates; elevation of all three tumor markers after treatment was a strongest indicator of poor survival. These patients should be considered to have received insufficient resection despite anatomical hepatectomy with curative intent and the absence of residual HCC tumors on CT examination after hepatectomy.

The recurrence rates were high regardless of the number of post-treatment tumor markers; recurrence was detected in more than 40% of patients, even in patients without elevated tumor markers after hepatectomy (Fig. 2). This is partly due to the high rate of recurrence of HCC even after curative treatment including multicentric occurrence [26]. Therefore, the sensitivity of the elevated post-treatment tumor markers in predicting recurrence is not high and, conversely, the absence of elevated tumor markers after treatment does not necessarily indicate a low risk of recurrence. However, the time to recurrence after treatment is an important factor for prognosis, and the number of elevated tumor markers after hepatectomy well discriminated recurrence rates when the time to recurrence was taken into account.

This study has several limitations. All three post-treatment tumor markers were measured at one time in the same serum sample despite differences in the half-lives between AFP/AFP-L3 and DCP, and was not strictly based on the half-lives of each marker. It was difficult to obtain serum samples at multiple occasions in a short period, after hepatectomy in clinical settings. We, therefore, measured all tumor markers between 1 and 2 months after hepatectomy, considering that the values of post-treatment tumor markers were not influenced by the pretreatment elevation during this period. Since none of our patients were treated with liver transplantation, we do not have data on the changes in the number of elevated tumor markers when patients undergo liver transplantation. Such analysis should be performed in the future. In addition, the association between number of elevated post-treatment tumor markers and status of the remnant liver after hepatectomy, including the residue of minute HCC cells undetected by imaging modalities, remains unknown. However, we hope this will be investigated in the future to shed light on the mechanisms behind the elevation of tumor markers after hepatectomy.

In conclusion, in our examination of 173 patients treated with hepatectomy with curative intent, the combination of three tumor markers measured after treatment had high discriminatory ability for survival and recurrence after hepatectomy. Further studies are warranted to confirm this association in other populations.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jhep.2012.07.018>.

References

[1] Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2002;55:74–108.

[2] Befeler AS, DiBisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology* 2002;122:1609–1619.

[3] Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. *Hepatol Res* 2007;37:S95–100.

[4] Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328:1797–1801.

[5] Taketa K, Sekiya C, Namiki N, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. *Gastroenterology* 1990;99:508–518.

[6] Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. *N Engl J Med* 1984;310:1427–1431.

[7] Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. *Oncology* 2002;62:S57–S63.

[8] Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2006;4:111–117.

[9] Kang SH, Kim DY, Jeon SM, Ahn SH, Park JY, Kim SU, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. *Eur J Gastroenterol Hepatol* 2012;24:849–856.

[10] Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: J-HCC guidelines. *J Gastroenterol* 2009;44:S119–121.

[11] Ramerz R. AFP (alpha-fetoprotein). In: Thomas L, editor. *Clinical and Laboratory Diagnosis*. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; 1998. p. 941–945.

[12] Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. *Cancer* 1992;69:31–38.

[13] Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. *Anal Biochem* 2009;388:306–311.

[14] Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology* 1994;19:61–66.

[15] Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. *Cancer* 2000;88:529–537.

[16] Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, et al. Clinical utility of high sensitive *Leus culinaris* agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/ml. *Cancer Sci* 2011;102:1025–1031.

[17] Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathological features of solitary hepatocellular carcinoma. *Cancer* 2000;88:544–549.

[18] Kaplan EL, Meier P. Non parametric estimation for incomplete observation. *J Am Stat Assoc* 1958;53:457–481.

[19] Petro R, Pike MC. Conservation of the approximation (0–E2)/E in the log rank test for survival data on tumor incidence data. *Biometrics* 1973;29:579–584.

[20] Cox D. Regression models and life tables. *J R Stat Soc* 1972;34:187–220.

[21] Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973;60:646–649.

[22] Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S, Tani M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful predictor of a poor survival. *Ann Surg* 2011;254:984–991.

[23] Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. *Cancer* 1998;83:2076–2082.

[24] Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. *Cancer* 2001;91:561–569.

[25] Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma. *Ann Surg* 2011;254:326–332.

[26] Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. *Hepatology* 1997;25:87–92.

Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: Is it really the effect of the therapy?

To the Editor:

Ogawa *et al.* reported interesting and important findings, based on a large prospective cohort, regarding the effect of combination therapy with peginterferon and ribavirin on the incidence of hepatocellular carcinoma (HCC) [1]. They reported lower incidence of HCC after treatment in patients with transient virological response (TVR, defined as relapse or breakthrough), as well as in patients with sustained virological response (SVR), relative to patients with non-virological response (NVR). The suppressive effect of this antiviral therapy on the development of HCC in patients with SVR has been established by several reports and can be explained by the eradication of hepatitis C virus (HCV), resulting in the release of inflammation and improvement of liver fibrosis [2]. However, it is unclear why the incidence of HCC after treatment was also lower in patients with TVR than in those with NVR, despite the persistence of viremia after treatment. Ogawa *et al.* attributed this observation to the preventive effect of complete HCV suppression during therapy on the development of HCC.

Previously reported viral and host factors that are strongly associated with response to antiviral therapy with peginterferon and ribavirin [3,4] may also be associated with the pathogenesis of HCC. Amino acid substitutions in the HCV core region, a viral factor reportedly associated with the response to peginterferon and ribavirin therapy in patients with HCV genotype 1b [3] (i.e., the vast majority of subjects in the study by Ogawa *et al.*), are also associated with the development of HCC [5]. Regarding host factors associated with the response to combination therapy [4], genetic polymorphisms near the *IL28B* gene are reportedly associated with hepatic steatosis [6] and interact with amino acid substitutions in the HCV core region [5,7]. Both hepatic steatosis and amino acid substitutions in the HCV core region are associated with the development of HCC [5,8]. In addition, amino acid substitutions in the HCV core region are reportedly associated with the development of HCC, even in patients who achieved SVR [9]. Ogawa *et al.* reported, without providing detailed data, a higher incidence of HCC in patients bearing the non-TT genotype of rs8099917 near the *IL28B* gene, which is unfavorable to response to the combination therapy; this observation is also consistent with our previous report [10].

These results suggest that differences in HCC incidence based on the outcome of antiviral combination therapy are mainly attributable to these viral and host factors. It is possible that Ogawa *et al.* simply classified patients based on the likelihood of developing HCC upon observing the response to the combination therapy (i.e., TVR and NVR). It would be interesting if the authors were to analyze the incidence of HCC in relation to the outcome of combination therapy based on these host and viral factors. In addition, it would be interesting to investigate genetic polymor-

phisms near the *IL28B* gene and amino acid substitutions at residue 70 of the HCV core region, in the 13 patients who developed HCC despite the achievement of SVR.

Given the existence of factors associated with both therapeutic response and incidence of HCC, one should be cautious in drawing the conclusion that lower incidence of HCC in patients with TVR, relative to those with NVR, actually reflects the "suppressive effect" of peginterferon and ribavirin combination therapy on hepatocarcinogenesis.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

References

- [1] Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. *J Hepatol*, in press.
- [2] Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 2000;132:517-524.
- [3] Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005;48:372-380.
- [4] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399-401.
- [5] Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, et al. The complicated relationships of amino acid substitution in HCV core region and *IL28B* genotype influencing hepatocarcinogenesis. *Hepatology* 2012;56:2134-2141.
- [6] Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, et al. Beneficial *IL28B* genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. *J Hepatol* 2011;55:1195-1200.
- [7] Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common variation of *IL28* affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. *J Hepatol* 2010;53:439-443.
- [8] Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. *Cancer* 2007;109:2490-2496.
- [9] Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. *J Med Virol* 2011;83:1016-1022.
- [10] Toyoda H, Kumada T. Incidence of hepatocellular carcinoma and response to interferon therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC. *Liver Int* 2012;32:1029-1031.



Letter to the Editor

Hidehiko Toyoda*

Takashi Kumada

Toshifumi Tada

Department of Gastroenterology,

Ogaki Municipal Hospital, Japan

*Corresponding author.

E-mail address: hmtoyoda@spice.ocn.ne.jp (H. Toyoda)

Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy

Hidenori Toyoda^{1,*}, Takashi Kumada¹, Toshifumi Tada¹, Takuro Niinomi¹, Takanori Ito¹, Yasuhiro Sone², Yuji Kaneoka³, Atsuyuki Maeda³

¹Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan; ²Department of Radiology, Ogaki Municipal Hospital, Ogaki, Japan; ³Department of Surgery, Ogaki Municipal Hospital, Ogaki, Japan

Background & Aims: The gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) often depicts non-hypervascular hypointense hepatic nodules during the hepatobiliary phase in patients with hepatocellular carcinoma (HCC). It is unclear whether the presence of these nodules is associated with HCC recurrence after hepatectomy. We conducted a prospective observational study to investigate the impact of the presence of non-hypervascular hypointense hepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI on the recurrence of HCC after hepatectomy. **Methods:** A total of 77 patients who underwent hepatectomy for primary, non-recurrent, hypervascular HCC were prospectively followed up after hepatectomy. Post-operative recurrence rates were compared according to the presence of non-hypervascular hypointense nodules on preoperative Gd-EOB-DTPA-enhanced MRI.

Results: Recurrence rates after hepatectomy were higher in patients with non-hypervascular hypointense nodules (risk ratio 1.9396 [1.3615–2.7222]) and the presence of non-hypervascular hypointense nodules was an independent factor associated with postoperative recurrence (risk ratio 2.1767 [1.5089–3.1105]) along with HCC differentiation and portal vein invasion. While no differences were found in the rate of intrahepatic metastasis recurrence based on the preoperative presence of non-hypervascular hypointense hepatic nodules, the rate of multicentric recurrence was significantly higher in patients with preoperative non-hypervascular hypointense hepatic nodules.

Conclusions: Patients with preoperative non-hypervascular hypointense hepatic nodules detected during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI are at higher risk of HCC recurrence after hepatectomy, mainly due to multicentric recurrence. © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer-related death [1,2]. In Japan, HCC is the third and fifth most common cause of death from cancer in men and women, respectively [3]. Tremendous efforts have been made to improve various imaging techniques, including ultrasonography (US), multidetector-row computed tomography (MDCT) [4,5], and magnetic resonance imaging (MRI) [6], for the detection of hepatic nodules, including small early-stage HCC tumors in high-risk patients under surveillance.

The liver-specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), which is taken up by hepatocytes, has been in clinical use for dynamic MRI studies since February 2008 in Japan. Gd-EOB-DTPA provides both dynamic and liver-specific hepatobiliary MR images [7–10]. In the hepatobiliary phase, hepatic lesions that lack normally functioning hepatocytes are imaged as an absence of hepatocyte-selective enhancement as compared with normal parenchyma [10,11]. The use of Gd-EOB-DTPA-enhanced MRI increases detection of concurrent non-hypervascular hepatic nodules as hypointense nodules during the hepatobiliary phase in patients with HCC. It is controversial whether the presence of these non-hypervascular hepatic nodules detected in patients with typical hypervascular HCC lesions has an impact on the recurrence of HCC after treatment.

In the present study, we attempted to evaluate the impact of concurrent non-hypervascular hepatic nodules detected as hypointense nodules during the hepatobiliary phase of Gd-EOB-

Keywords: Hepatocellular carcinoma; Gd-EOB-DTPA-enhanced MRI; Non-hypervascular hypointense nodule; Hepatobiliary phase; Hepatectomy; Recurrence. Received 29 November 2012; received in revised form 4 January 2013; accepted 24 January 2013

* Corresponding author. Address: Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. Tel.: +81 584 81 3341; fax: +81 584 75 5715.

E-mail address: hmtoyoda@spice.ocn.ne.jp (H. Toyoda).

Abbreviations: Gd-EOB-DTPA, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; MRI, magnetic resonance imaging; HCC, hepatocellular carcinoma; US, ultrasonography; MDCT, multidetector-row computed tomography; TFE, turbo field echo; CTHA, computed tomography during hepatic arteriography.



Research Article

Table 1. Comparison of clinical characteristics of study patients based on the presence of non-hypervascular hypointense nodules detected during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI (n = 77).

	Non-hypervascular hypointense nodule (+) (n = 18)	Non-hypervascular hypointense nodule (-) (n = 59)	p value
Age (mean ± SD, yr) (range)	65.8 ± 9.0 (46-76)	69.1 ± 7.0 (53-82)	0.2727
Sex (female/male)	3 (16.7)/15 (83.3)	18 (30.5)/41 (69.5)	0.3921
Etiology (HBV/HCV/non-HBV, non-HCV)	2 (11.1)/11 (61.1)/5 (27.8)	9 (15.3)/39 (66.1)/11 (18.6)	0.6796
Child-Pugh class (A/B)*	17 (94.4)/1 (5.6)	58 (98.3)/1 (1.7)	0.9474
Albumin (mean ± SD, g/dl)	3.91 ± 0.51	4.08 ± 0.32	0.1664
Total bilirubin (mean ± SD, mg/dl)	0.88 ± 0.36	0.84 ± 0.33	0.7296
15-minute ICG retention rate (%)	18.1 ± 5.4	16.0 ± 6.7	0.2405
Prothrombin (%)	95.3 ± 15.6	95.1 ± 11.2	0.9105
Platelet count (x10 ⁹ /ml)	132 ± 47	152 ± 66	0.5433
Tumor size (mean ± SD, cm) (range)	2.52 ± 0.99 (1.3-4.7)	2.84 ± 1.54 (1.0-8.6)	0.6600
Number of tumors (single/multiple)	15 (83.3)/3 (16.7)	53 (89.8)/6 (10.2)	0.7358
Portal vein invasion (absent/present)**	17 (94.4)/1 (5.6)	50 (84.7)/9 (15.3)	0.4989
Differentiation (well-/moderately or poorly)**	7 (38.9)/11 (61.1)	21 (35.6)/38 (64.4)	0.9999
Growth pattern (expansive/infiltrative)**	14 (77.8)/4 (22.2)	52 (88.1)/7 (11.9)	0.4718
Follow-up period (months) (median, range)	31.3 (9.4-53.9)	34.9 (8.5-55.4)	0.4200

Percentages are in parentheses.

HBV, hepatitis B virus; HCV, hepatitis C virus; ICG, indocyanine green test.

* Child-Pugh class A includes patients without cirrhosis.

** Evaluated by pathologic examination based on resected specimens.

DTPA-enhanced MRI on postoperative recurrence in patients who underwent hepatectomy with curative intent for HCC.

Materials and methods

Patients, treatment and follow-up

This prospective study was conducted after the approval by the hospital institutional review board and carried out in compliance with the Helsinki Declaration. Patient enrollment was carried out between February 2008 and December 2011. A total of 102 patients underwent hepatectomy as a curative treatment for primary, non-recurrent HCC during the study period at Ogaki Municipal Hospital. Gd-EOB-DTPA-enhanced MRI could not be performed prior to hepatectomy in 25 patients, including 11 patients who had been referred from another institution only for hepatectomy and 14 patients who could not receive examination due to metal implants, history of allergy to contrast medium, tattoos, or claustrophobia. The remaining 77 patients who underwent Gd-EOB-DTPA-enhanced MRI within 2 weeks prior to hepatectomy were studied. The initial diagnosis of HCC before treatment was based on appropriate imaging characteristics according to criteria of the guidelines by the American Association for the Study of Liver Diseases [12,13]. The final diagnosis of HCC was confirmed by pathologic diagnosis of resected specimens.

Decisions regarding individual treatments were based on Japanese treatment guidelines for HCC [14]. In all patients, HCC tumors were resected with ample margins; enucleation of tumors without margins was not performed.

After hepatectomy, all patients were prospectively followed from 8.5 months to 55.4 months (median follow-up, 34.1 months) until the end of September 2012 at our institution, with US and either MDCT or MRI every 3–6 months. Regular monitoring of serum tumor markers (alpha-fetoprotein, *Lens culinaris* agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxy prothrombin) was performed every 3 months. When an elevation in tumor markers was detected, additional imaging (usually MDCT or MRI) was performed to check for HCC recurrence. Recurrence was diagnosed by pathologic examination of resected specimens when patients underwent re-hepatectomy. In the remaining patients, HCC was diagnosed by appropriate imaging characteristics according to criteria

of the guidelines by the American Association for the Study of Liver Diseases [12,13]. Recurrent HCC was categorized into two groups prior to the study, as intrahepatic metastasis recurrence or multicentric recurrence according to a previous study [15,16]. Intrahepatic metastasis recurrence was defined as recurrent tumors consisting of moderately or poorly differentiated HCC with the same or lower degree of differentiation than the primary tumors on pathologic examination or hypervascular tumor without non-hypervascular peripheral regions in a same hepatic segment on imaging examination. Multicentric recurrence was defined according to previously reported criteria with some modifications [17,18] as follows: (i) the recurrent tumor consists of well-differentiated HCC occurring in a different hepatic segment, than moderately or poorly differentiated pre-existing HCCs; (ii) both the primary and recurrent tumors are well-differentiated HCCs; and (iii) the recurrent tumor contained regions of dysplastic nodules in peripheral areas based on pathologic examination or contained non-hypervascular regions in peripheral areas of hypervascular tumor on imaging examination.

Preoperative imaging examinations of liver nodules by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI and confirmation of non-hypervascular hypointense hepatic nodules

All patients underwent Gd-EOB-DTPA-enhanced MRI within 2 weeks of hepatectomy. MRI was performed using a 1.5-T whole-body MRI system (Intera Achieva 1.5T NOVA; Philips Medical Systems) with a phased-array body coil as the receiver coil. T1-weighted sequences were acquired with the following parameters: T1-weighted turbo field echo (TFE) in-phase and opposed-phase transverse (TE, opposed-phase 2.3, in-phase 4.6; flip angle, 12°; matrix size, 256 × 512; scan percentage, 70) with 3.5-mm section thickness, a 0-mm intersection gap, and a 38-cm field of view. After intravenous injection of Gd-EOB-DTPA (Primovist; Bayer Schering Pharma, Osaka, Japan), T1-weighted transverse gradient-echo sequences (high-resolution isotropic volume examination [THRIVE] with spectral presaturation with inversion recovery [SPIR], 4/1.8; flip angle, 12°; matrix size, 256 × 512; scan percentage, 78.54) with 3.5-mm section thickness, a 0-mm intersection gap, and a 38-cm field of view were obtained. Gd-EOB-DTPA was administered intravenously as a bolus at a rate of 2 ml/s (0.1 ml/kg, maximum dose of 10 ml) through an intravenous cubital line (20–22 gauge), which was flushed with 20 ml of saline using a power injector (Sonic Shot; Nemoto Kyorindo, Tokyo, Japan). The timing for dynamic arterial phase imaging was determined using